+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Human Embryonic Stem Cells Market - Segmented by Application and Geography - Growth, Trends, and Forecasts (2018 - 2023)

  • ID: 4591631
  • Report
  • Region: Global
  • 110 pages
  • Mordor Intelligence
1 of 4


  • BD Biosciences
  • Cellartis AB
  • Geron Corporation
  • Invitrogen Corporation
  • Millipore Corporation
  • Tataa Biocenter
  • MORE
The global embryonic stem cell market is expected to register a CAGR of 10% during the forecast period of 2018-2023. Due to the high prevalence of cardiac and malignant diseases, North America dominates the market.

Rising Demand for Regenerative Medicines

Government funding for the development of regenerative medicine has been increasing in most developed countries, because of its applications in organ transplantation, tissue engineering and various other applications. In the United States, two major government agencies, National Institutes of Health (NIH) and California Institute of Regenerative Medicine (CIRM), fund almost all the translational research and regenerative medicine development in the country. It is estimated that the US government invests around USD 800-900 million every year in stem cell research. The rising demand for regenerative medicine is fuelling the growth of the human embryonic stem cells market.

Additionally, high prevalence of cardiac and malignant diseases, increasing R&D investments and research initiatives, increasing support from government and private institutions, and increasing prevalence of genetic disorders are driving the human embryonic stem cells market.

Ethical and Moral Framework

Stem cells are often considered as a hopeful alternative form of therapies. However, there has been a strong debate over the use of stem cells in the development of novel therapies, as stem cell banking raises ethical and legal issues that highlight the need for a careful regulatory framework. The increasing tensions between public and private models of banking may require the adoption of an ethical framework. Several national and international regulatory firms have addressed these issues. For instance, in Europe, the European Group on the Ethics of Science and New Technologies stated that it should be freely done and the donor does not have any payment or reward. Therefore, such ethical and moral frameworks are hindering the growth of the human embryonic stem cell market. Other factors, such as expensive procedures and regulatory complications, are also hindering the growth of the market.

Additionally, stringent regulations by the government are restraining the growth of the human embryonic stem cell market.

North America Dominates the Market

Due to the extensive therapeutic research activities in the United States and government funding, North America dominates the market. Additionally, the FDA has approved clinical trials, which indicated the use of stem cells in treating various diseases. Thus, these factors are responsible for the growth of the North American segment of the market studied.

Key Developments in the Market
  • December 2017: Viacyte Inc. was approved a grant by the California Institute for Regenerative Medicine (CIRM), for the initial development of immune-evasive pluripotent stem cell lines.
Major Players: Australian Stem Cell Centre, BD Biosciences, Cellartis AB, Millipore Corporation, Geron Corporation, Invitrogen Corporation, Viacyte, SA Biosciences Corporation, Tataa Biocenter, Thermo Scientific, and Vitrolife AB, among others.

Reasons to Purchase this Report
  • Market analysis for the human embryonic stem cell banking market, with region-specific assessments and competition analysis on global and regional scales.
  • Analyzing various perspectives of the industry, with the help of Porter’s five forces analysis.
  • The treatment type that is expected to dominate the market.
  • The regions that are expected to witness the fastest growth during the forecast period.
  • Identify the latest developments, market shares, and strategies employed by the major market players.
  • 3 months analyst support along with the Market Estimate sheet (in excel).
Customization of the Report

This report can be customized to meet your requirements.
Note: Product cover images may vary from those shown
2 of 4


  • BD Biosciences
  • Cellartis AB
  • Geron Corporation
  • Invitrogen Corporation
  • Millipore Corporation
  • Tataa Biocenter
  • MORE
1. Introduction
1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Driver
6.1.1 High Prevalence of Cardiac and Malignant Diseases
6.1.2 Increasing R&D Investments and Research Initiatives
6.1.3 Rising Demand for Regenerative Medicines
6.1.4 Increasing Support from Government and Private Institutions
6.1.5 Increasing Prevalence of Genetic Disorders
6.2 Market Restraint
6.2.1 Expensive Procedure
6.2.2 Stringent Regulatory Guidelines
6.2.3 Ethical and Moral Concerns
6.3 Opportunities
6.4 Key Challenges

7. Market Segmentation
7.1 By Application
7.1.1 Regenerative Medicine
7.1.2 Stem Cell Biology Research
7.1.3 Tissue Engineering
7.1.4 Toxicology Testing
7.2 By Geography
7.2.1 North America United States Canada Mexico
7.2.2 Europe France Germany United Kingdom Italy Spain Rest of Europe
7.2.3 Asia-Pacific China Japan India Australia & New Zealand South Korea Rest of Asia-Pacific
7.2.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
7.2.5 South America Brazil Argentina Rest of South America

8. Competitive Landscape
8.1 Merger & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches

9. Key Players
9.1 Australian Stem Cell Centre
9.2 BD Biosciences
9.3 Cellartis AB
9.4 Geron Corporation
9.5 Invitrogen Corporation
9.6 Millipore Corporation
9.7 SA Biosciences Corporation
9.8 Tataa Biocenter
9.9 Thermo Scientific
9.10 Viacyte
9.11 Vitrolife AB
* List Not Exhaustive

10. Future of the Market
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Australian Stem Cell Centre
  • BD Biosciences
  • Cellartis AB
  • Millipore Corporation
  • Geron Corporation
  • Invitrogen Corporation
  • Viacyte
  • SA Biosciences Corporation
  • Tataa Biocenter
  • Thermo Scientific
  • Vitrolife AB
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4591631